i
COVID-19 state of vaccine confidence insights report ; report 24, March 28, 2022
-
March 28, 2022
-
[PDF-826.51 KB]
Details:
-
Corporate Authors:
-
Description:Date Range: February 1 – 21, 2022
Major Themes
• Consumers’ interest in new COVID-19 vaccines from Ocugen-Bharat Biotech and Novavax, which are not yet FDA-authorized, but are WHO prequalified.
• Continued discussions on infection-induced immunity versus vaccine-induced immunity among the public.
• Increasing public perception that the pandemic is over; support for community mitigation efforts is waning.
• New and Emerging Myths
o Myth emerged about a syndrome called Vaccine Acquired Immune Deficiency Syndrome (VAIDS).
• Continuing and Evolving
o Some parents are disappointed in the delay of COVID-19 vaccines for children less than 5 years old while others are strongly opposed to pediatric vaccines.
Ways to take action. Federal, state, and local partners should continue to work together to explain the rationale for updated guidance, respond to gaps in information, and confront misinformation with evidence-based messaging. These efforts aim to increase confidence in COVID-19 vaccines and expand vaccine uptake more broadly. Partners should create and disseminate messages about the safety and effectiveness of COVID-19 primary series vaccination and a booster dose compared to getting immunity by being infected with the SARS-CoV-2 that causes COVID-19 (known as infection-induced immunity). CS000000-A | 3/28/22
SoVC_report24.pdf
-
Subjects:
-
Series:
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
